{"id":"NCT00452439","sponsor":"M.D. Anderson Cancer Center","briefTitle":"A Study of Actonel for the Prevention of Bone Loss","officialTitle":"A Randomized, Double Blinded Study of Actonel for the Prevention of Bone Loss in Patients Receiving High Dose Corticosteroids for the Treatment of Acute Lymphocytic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-02","primaryCompletion":"2014-08","completion":"2014-08","firstPosted":"2007-03-27","resultsPosted":"2020-12-28","lastUpdate":"2020-12-28"},"enrollment":72,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Leukemia","Lymphoma"],"interventions":[{"type":"DRUG","name":"Actonel (Risedronate)","otherNames":["Risedronate Sodium"]},{"type":"DIETARY_SUPPLEMENT","name":"Calcium","otherNames":[]},{"type":"DIETARY_SUPPLEMENT","name":"Vitamin D","otherNames":[]}],"arms":[{"label":"Actonel","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The goal of this clinical research study is to learn if Actonel (risedronate) can help to prevent the development of osteoporosis (brittle and weak bones) caused by the steroid medication used to treat leukemia. The safety of this treatment in patients with ALL or LL will also be studied.","primaryOutcome":{"measure":"Bone Loss Reduction: Mean Percent Changes in BMD for Each Treatment Arm at the 6 Months","timeFrame":"6 months","effectByArm":[{"arm":"Actonel","deltaMin":-2.4,"sd":0.05},{"arm":"Placebo","deltaMin":-3.5,"sd":0.04}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.mdanderson.org"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":36},"commonTop":[]}}